# About Medicinal CJC-1295: An Independent Research Digest

> Medicinal CJC-1295 is an independent editorial project summarizing the peer-reviewed CJC-1295 literature. Not a clinic, not a pharmacy, not a vendor — a console reading of the record.

What this site is, what it is not, and the standard it holds itself to: every claim logged to a study, every form distinguished, every gap in the human evidence left visible.

## What Medicinal CJC-1295 is

Medicinal CJC-1295 is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The project exists because the CJC-1295 record is unusually easy to get wrong. The single most common error — in marketing, in forums, in casual reference — is conflating the multi-day DAC conjugate with the short-acting no-DAC "Modified GRF 1-29" form, two molecules that share a backbone but differ by an entire half-life. We built the site as a console reading of the literature specifically so that distinction, and others like it, stay legible: each finding logged to its study, each form tagged, each number traceable to a source.

## The "medicinal" in the name

The word "medicinal" in this domain is editorial framing — a position this publisher occupies relative to the literature, not a claim about the site's services. It signals that the site reads CJC-1295 the way a careful reader of the medical literature would: by who studied it, what the controlled data show, where the human evidence stops, and what the regulatory record says. It does not mean the site offers treatment, consultation, prescriptions, or any product. There is no clinic behind this console, no pharmacy, and no checkout.

That framing carries an obligation. Reading the record honestly means surfacing the gaps as plainly as the findings — that CJC-1295 is not FDA-approved, that the 2024 Pharmacy Compounding Advisory Committee did not recommend it for the 503A bulks list, that it is prohibited at all times in sport under WADA Section S2, and that the human evidence base remains limited to early pharmacokinetic studies. A digest that only quoted the impressive numbers would be a worse digest.

## How we handle the evidence

Every quantitative claim on this site is tied to a numbered citation in the [full reference list](/references), drawn from the published literature: PubMed-indexed journals, the primary pharmacokinetic papers, structural-biology and analytical-chemistry studies, and recent reviews. We describe what was administered, to which species, at which dose, by which route — never what a person should take. We distinguish the DAC and no-DAC forms wherever a finding is form-specific. And we flag the limits of the record, including the points where chemical registries themselves disagree, rather than papering over them.

The result is meant to be a reference a careful reader can trust and check — a sourced, form-aware summary of what the CJC-1295 literature actually measured, with nothing asserted that is not logged below it.

---

An emerald-on-black console reading of the CJC-1295 record — the four substitutions, the DAC albumin handle, and the multi-day-versus-short-acting half-life each logged to its study and split by form, with no clinic behind the panel and nothing here dispensed or sold.